Sementis is developing vaccines for the prevention of diseases caused by RNA viruses including Chikungunya and Zika virus infections. The vaccines are developed using the Sementis Copenhagen Vector (SCV) technology, which uses a replication-incompetent vaccinia virus to stimulate B and T cell immune responses against the disease antigens incorporated in the vector, using recombinant genetic technologies. The Chikungunya vaccine is co-developed by Sementis and the University of South Australia. Vaccines will be administered through Enesi Pharma's ImplaVax® technology. Preclinical development is underway for Chikungunya early research is underway for Zika virus infections in Australia.
ImplaVax® is an innovative and proprietary needle-free solid dose implant and device technology for subcutaneous vaccination. ImplaVax-enabled vaccines can deliver superior immune responses, compared with standard injection protocols, having other benefits such as safety, ease of use, reliability and stability.
As at April 2019, no recent reports of development had been identified for preclinical development in Chikungunya-virus-infections (Prevention) in Australia (SC).
As at March 2020, no recent reports of development had been identified for research development in Zika-virus-infection (Prevention) in Australia (SC).
In November 2018, Enesi Pharma entered into a research collaboration agreement with Sementis to develop and evaluate the solid dose versions of Sementis' lead peanut hypo-allergy vaccine and single vectored Chikungunya/Zika vaccine candidates for administration via Enesi Pharma's ImplaVax® technology. Under the terms of the agreement, Enesi will formulate solid dose implants based on SCV vaccine provided by Sementis, and Sementis will undertake safety and immunogenicity testing, and preclinical development. 
The University of South Australia expanded their earlier collaboration with Sementis to include Zika virus vaccine. The organisations had collaborated earlier for the development of the Chikungunya vaccine  .
Sementis is collaborating with the QIMR Berghofer Medical Research Institute to conduct Chikungunya challenge studies to test efficacy of Sementis’ Chikungunya vaccine (Sementis company presentation, November 2015).
Key Development Milestones
Sementis' single vectored RNA virus vaccine showed effectiveness in proof-of-concept studies in mice by protecting against Zika and chikungunya from a single vaccination shot  .
In a preclinical study mice were vaccinated with either with SCV 301C vaccine, a vaccinia virus or a placebo and then challenged with Chikungunya virus. SCV 301C vaccination prevented viral replication and viral spread via the blood stream, compared with the vaccinia virus and placebo groups that were infected with Chikungunya virus that indicated no changes (Sementis company presentation, March 2015).